Pricing
  1. US-listed companies
  2. Tonix Pharmaceuticals Holding Corp.
  3. Financials
  4. Stock-based compensation

Tonix Pharmaceuticals Holding Corp. (TNXP)

Market cap
$122.55M
P/E ratio
SummaryFinancials
Period EndStock-based compensation (Million USD)YoY (%)
Dec 31, 20245-48.49%
Dec 31, 20239-15.02%
Dec 31, 202211+38.17%
Dec 31, 20218+174.65%
Dec 31, 20203+97.39%
Dec 31, 20191-18.60%
Dec 31, 20172-45.19%
Dec 31, 20163-25.59%
Dec 31, 20154+42.13%
Dec 31, 20143-5.54%
Dec 31, 20133+110.65%
Dec 31, 20122+125.99%
Dec 31, 20111

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat